as 06-30-2025 3:30pm EST
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Founded: | 2005 | Country: | United States |
Employees: | N/A | City: | BEVERLY HILLS |
Market Cap: | 600.7M | IPO Year: | N/A |
Target Price: | $33.75 | AVG Volume (30 days): | 3.3M |
Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.42 | EPS Growth: | N/A |
52 Week Low/High: | $3.52 - $23.40 | Next Earning Date: | 08-06-2025 |
Revenue: | $17,363,588 | Revenue Growth: | -35.92% |
Revenue Growth (this year): | 258.96% | Revenue Growth (next year): | 8.02% |
CAPR Breaking Stock News: Dive into CAPR Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
The Fly
5 days ago
MT Newswires
5 days ago
TipRanks
6 days ago
TipRanks
6 days ago
MT Newswires
7 days ago
GlobeNewswire
7 days ago
MT Newswires
8 days ago
The information presented on this page, "CAPR Capricor Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.